Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2019-01-17
Target enrollment:
Participant gender:
Summary
This is a Phase 2a study designed to assess the safety and tolerability of MEDI0382 titrated
up to a dose level of 100, 200 or 300 µg from 50 µg vs Placebo across 48 days in Japanese
subjects.
The study D5674C00001 can be conducted with a reasonable expectation of safety and
tolerability in Japanese T2DM patients. The design of this study has taken into account the
known benefits and risks of GLP-1 receptor agonists and glucagon receptor agonists as well as
the translatable effects observed in nonclinical studies of MEDI0382.